News Releases | Insmed Incorporated

Month Year

Email Alerts

Oct 26, 2023

Insmed Ranks No. 1 on Science's 2023 Top Biopharma Employers List

Read more
Oct 26, 2023

Insmed Reports Third-Quarter 2023 Financial Results and Provides Business Update

Read more
Oct 24, 2023

Insmed and Google Cloud Collaborate to Transform the Lives of Patients by Harnessing the Power of AI

Read more
Oct 12, 2023

Insmed to Host Third-Quarter 2023 Financial Results Conference Call on Thursday, October 26, 2023

Read more
Oct 6, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Sep 26, 2023

Insmed To Present at Chardan's 7th Annual Genetic Medicines Conference

Read more
Sep 8, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Sep 6, 2023

Insmed To Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Read more
Sep 5, 2023

INSMED ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ARISE STUDY OF ARIKAYCE® (AMIKACIN LIPOSOME INHALATION SUSPENSION) IN PATIENTS WITH NTM LUNG DISEASE CAUSED BY MAC

Read more
Aug 4, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Aug 3, 2023

Insmed Reports Second-Quarter 2023 Financial Results and Provides Business Update

Read more
Jul 20, 2023

Insmed to Host Second-Quarter 2023 Financial Results Conference Call on Thursday, August 3, 2023

Read more
Jul 7, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Jun 7, 2023

Insmed To Present at the Goldman Sachs 44th Annual Global Healthcare Conference

Read more
Jun 6, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
May 22, 2023

Insmed Presents Range of New Study Findings at American Thoracic Society 2023 International Conference

Read more
May 8, 2023

Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, "The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More"

Read more
May 5, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
May 4, 2023

Insmed Reports First Quarter 2023 Financial Results and Provides Business Update

Read more
Apr 24, 2023

Insmed to Host Investor and Analyst Event on May 8, 2023

Read more
Apr 20, 2023

Insmed to Host First Quarter 2023 Financial Results Conference Call on Thursday, May 4, 2023

Read more
Apr 6, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more
Mar 31, 2023

Insmed Completes Enrollment of Adult Patients in Phase 3 ASPEN Study of Brensocatib in Bronchiectasis

Read more
Mar 24, 2023

Insmed to Present New Clinical, Pre-Clinical, and Real-World Data in Serious and Rare Lung Diseases at the American Thoracic Society 2023 International Conference

Read more
Mar 3, 2023

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Read more

Show per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your email alerts.

Investor Presentation

View the latest Insmed Investor Presentation

Download

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa

Company

Our Global Company

Patients

Current Clinical Trials

Science

Therapies

Responsibility

Responsibility in Action

Press Releases

Company

Our Global Company

Patients

Current Clinical Trials

Science

Therapies

Responsibility

Responsibility in Action

Footer